ADB-FUBINACA

 

Buy ADB-FUBINACA from http://www.dealchemical.com

 

Formal Name N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
CAS Number 1445583-51-6
Molecular Formula C21H23FN4O2
Formula Weight 382.4
Purity ‚Č•98%
Formulation A neat solid
SMILES O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3
InChI Code InChI=1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28)
InChI Key ZSSGCSINPVBLQD-UHFFFAOYSA-N
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

ADB-FUBINACA is a synthetic cannabinoid that has recently been identified in herbal blends. Its name refers to its structure, which has a 1-amino-3,3-dimethyl-1-oxobutan-2-yl (ADB) group linked to a 4-fluorobenzyl-1H-indazole-3-carboxamide (FUBINACA) base at the amide group. The physiological and toxicological properties of this compound have not been determined. This product is intended for forensic and research applications.

ADB-Fubinaca is known as MAB-FUBINACA,ADBF,but it is NOT ADB-Pinaca.ADB-FUBINACA is a synthetic cannabinoid that has been identified in herbal blends in Janpan.ADB-FUBINACA features a carboxamide group at the 3-indazole position, like STS-135 and SDB-001. ADB-FUBINACA is perfered to be the product of rational drug design

ADB-Fubinaca or MAB-FUBINACA experience(effects)

The enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a a potent agonist of the CB1 receptor and CB2 receptor with a EC50 value of 1.2 nM and 3.5 nM respectively.

ADB-Fubinaca or MAB-FUBINACA review

The physiological and toxicological properties of this compound have not been determined. This product is intended for forensic and research applications.